(ERAS) Erasca, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ERAS) Erasca, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Erasca, Inc. BCG Matrix is a company-specific strategy tool used to classify the business’s products or units into Stars, Cash Cows, Question Marks, and Dogs for faster portfolio and investment analysis. The page already shows a real preview of the actual report content, so you can review the format and depth before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
0 approved drugs
As of end-2025, Erasca, Inc. remained a clinical-stage oncology company, so it had 0 approved drugs to place in the Star quadrant. Without a marketed product, Erasca had no revenue-earning asset to pair high market share with high growth. In BCG terms, that leaves no Star position to support the portfolio.
0 product sales
Erasca, Inc. reported $0 commercial product revenue, so there is no approved medicine generating sales yet. Without sales, no franchise can dominate a growing market, and the company is still funding R&D rather than harvesting cash. That fits a Star label poorly and looks more like an early-stage pipeline bet than a commercial growth engine.
0 market share
Erasca, Inc. had no disclosed market share in approved drug markets, because its pipeline was still investigational and had no commercial drug sales. That means share is effectively not applicable, which fails a core BCG Star test: strong share in a growing market. In BCG terms, this sits outside "Stars" and closer to a pre-revenue R&D profile.
No late-stage commercial brand
Erasca, Inc. had no late-stage commercial brand at year-end 2025; its pipeline was still built around early clinical assets, so it did not meet the usual Stars test of a proven product with expansion upside in a fast-growing market. In BCG terms, that leaves the company reliant on pipeline execution, not on an established, revenue-generating brand.
- No launched brand in 2025
- Early-stage pipeline only
- No Star asset yet
R&D-only profile
Erasca, Inc. stayed centered on R&D for RAS/MAPK-driven cancers, so the portfolio is still promising but fully precommercial. With 0 approved products and no product revenue, it does not fit BCG Star status yet. The value sits in clinical readouts, not current cash generation.
- R&D-only, precommercial mix
- Focused on RAS/MAPK cancers
- 0 approved products
Erasca Misses Star Status: No Approved Drugs, No Revenue
Erasca, Inc. had no Star asset at end-2025 because it still had 0 approved drugs and $0 commercial product revenue. With no marketed brand, it had no disclosed market share in a growing drug market, so the BCG Star test was not met. Its value remained tied to clinical readouts, not cash flow.
| Metric | 2025 |
|---|---|
| Approved drugs | 0 |
| Commercial revenue | $0 |
| Market share | Not applicable |
What is included in the product
Detailed Word Document
BCG matrix overview of Erasca, Inc.’s pipeline, highlighting Stars, Question Marks, Cash Cows, and Dogs.
Editable Excel File
One-page Erasca, Inc. BCG Matrix that quickly reveals product priorities and reduces portfolio confusion
Reference Sources
Erasca, Inc. Reference Sources provide a credible trail that supports fast due diligence and smarter decision-making.
Cash Cows
0 mature products
Erasca, Inc. had 0 mature marketed therapies by end-2025, so it had no Cash Cow base in the BCG Matrix. Cash Cows need an established product with stable demand, high market share, and steady cash flow; Erasca still depended on its pipeline, not recurring product sales. In 2025, product revenue remained $0, so the company did not yet generate the cash needed for this quadrant.
0 recurring royalty stream
Erasca had 0 disclosed royalty-generating commercial products, so this was not a cash cow. Cash cows usually generate steady cash with little reinvestment, but Erasca reported no recurring royalty stream and remained tied to external financing. Its model stayed R&D heavy, with spending focused on pipeline work instead of harvestable cash flow.
0 steady sales franchise
Erasca, Inc. had 0 approved drugs in 2025, so it had no steady sales engine and no product revenue to fund the business. A cash cow needs a low-growth, high-share franchise that throws off cash, but Erasca had none of those traits. With no commercial launch, its 2025 profile stayed squarely in the R&D stage, not the cash-generating stage.
High R&D burn
Erasca, Inc. fit the opposite of a Cash Cow in FY2025: it had no meaningful cash generation from products, so funding came from financing and cash reserves, while R&D kept consuming capital to push the pipeline forward. That burn is the cost of building future value, not harvesting steady profits.
- FY2025 cash use was R&D-led, not revenue-led.
- No Cash Cow-style cash surplus was being produced.
- Pipeline advancement drove the spend.
No dividend funder
Erasca, Inc. was not a cash cow in 2025 because it had no product revenue to turn into operating cash, so it could not fund dividends or broad overhead from operations. Cash cows normally generate surplus cash for the rest of the business, but Erasca had not reached commercialization. That left funding dependent on cash reserves and external capital, not internal cash flow.
- No product cash flow in 2025
- No dividend support from operations
- Still in pre-cash-cow stage
Erasca Lacks a Cash Cow in FY2025
Erasca, Inc. had no Cash Cow in FY2025. Product revenue was $0, approved drugs were 0, and royalty products were 0, so there was no steady cash engine.
| FY2025 metric | Value |
|---|---|
| Product revenue | $0 |
| Approved drugs | 0 |
| Royalty products | 0 |
Cash use stayed R&D-led, not revenue-led, so Erasca remained in build mode. It could not fund growth from operations or generate surplus cash for a Cash Cow profile.
Preview Before You Purchase
Erasca, Inc. Reference Sources
The Erasca, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. It includes the full, professionally formatted report with no hidden changes or demo content. Once purchased, your download will be ready for immediate use in analysis, planning, or presentation. What you preview is what you get—simple, clear, and complete.
Dogs
0 low-growth commercial assets
Erasca, Inc. had 0 low-growth commercial assets in this BCG slot because it had no launched drug in a mature market. The Company remained a clinical-stage oncology biotech in 2025/2026, with no disclosed legacy product that fit the Dogs profile of weak growth and weak share. No commercial revenue from a marketed asset was reported.
0 divestiture targets
Erasca had 0 disclosed marketed brands to sell or wind down, so there were no clear divestiture targets in the classic Dogs bucket. Its portfolio was still mostly clinical-stage, with value tied to pipeline progress rather than legacy products. So, in BCG terms, Dogs was effectively empty for Erasca, Inc.
0 break-even product lines
Dogs usually break even and tie up capital, but Erasca, Inc. had 0 approved product lines to assess in this bucket. The Company was still pre-revenue from products, with 0 product sales in the latest fiscal period. So, this BCG quadrant does not yet apply to Erasca's pipeline.
0 obsolete revenue streams
Erasca, Inc. has no legacy products to classify as obsolete revenue streams, and its pipeline remains early-stage rather than mature. In BCG terms, that means there is no clear low-growth, low-share "Dog" cash trap; the company is still spending on development, not defending declining sales.
- No reported obsolete product line
- Pipeline is still pre-commercial
- No structurally declining revenue base
- No Dog-style cash trap
Precommercial portfolio only
Erasca, Inc.’s Dogs bucket was effectively empty because its portfolio was still investigational, with 0 approved products and no product revenue to drag on performance. That means the main risk was development failure, not a legacy low-growth franchise. In BCG terms, the capital was tied up in precommercial assets, so value depended on clinical readouts, not harvesting cash.
- 0 approved products
- No legacy commercial drag
- Risk = clinical uncertainty
Erasca’s Dogs Bucket: Empty, with Value Riding on Pipeline Readouts
Erasca, Inc. had no Dogs to classify in 2025/2026 because it had 0 approved products and no marketed revenue base. The Company stayed clinical-stage, so there was no low-growth legacy asset draining cash. In BCG terms, Dogs were effectively empty, and value still depended on pipeline readouts.
| Metric | Value |
|---|---|
| Approved products | 0 |
| Product revenue | $0 |
| Dogs bucket | Empty |
Question Marks
ERAS-007
ERAS-007 is Erasca, Inc.’s oral ERK1/2 inhibitor for targeted NSCLC, colorectal cancer, and AML, and it still sits in early clinical development. As an unapproved pipeline asset, it has no product revenue yet, so its value is still tied to trial data, not sales.
That makes ERAS-007 a classic Question Mark in the BCG Matrix: high upside if efficacy and safety hold, but high risk because it is still experimental. The market opportunity could be meaningful, but cash burn and clinical uncertainty remain the key constraints.
ERAS-601
ERAS-601 is an oral SHP2 inhibitor from Erasca, Inc. aimed at targeted advanced or metastatic solid tumors.
It was still in clinical development and had not yet shown clear differentiation, so it fit the Question Marks quadrant in the BCG Matrix.
Its move toward Star status depends on proof of stronger efficacy, safety, and market fit versus other SHP2 programs.
ERAS-801
ERAS-801 is Erasca, Inc.'s CNS-penetrant EGFR inhibitor for recurrent glioblastoma multiforme, a setting with high unmet need and limited targeted options. Glioblastoma remains the most common primary malignant brain tumor in adults, with about 3 cases per 100,000 people a year in the U.S., so any early-stage asset can scale fast if data land well. That makes ERAS-801 a classic Question Mark: high potential, but still low market share and clinical risk.
RAS/MAPK pipeline focus
Erasca’s RAS/MAPK focus sits in a high-growth "Question Mark" zone: the pathway is altered in about 30% of human cancers, so the market is big, but each program still needs proof of efficacy, safety, and payer value. That makes the theme strategically strong, yet commercially unproven.
- High-growth biology
- Large unmet need
- Clinical proof still needed
- Commercial value not yet set
2018-founded, San Diego based
Erasca, Inc. was founded in 2018 in San Diego, so at the end of 2025 it was only 7 years old. That puts it in the young clinical-biotech bucket: no approved drugs, no recurring product cash flow, and no Stars or Cash Cows yet. Its pipeline assets fit the Question Mark box until human data and regulatory wins show real traction.
- Founded 2018; still early-stage in 2025
- 7-year-old biotechs usually lack mature revenue
- Pipeline programs start as Question Marks
- Upgrades need data, approval, and sales
Erasca’s Big Bets: Early Pipeline, Big Uncertainty
Erasca, Inc.’s Question Marks are ERAS-007, ERAS-601, and ERAS-801: all are early-stage, unapproved pipeline assets with no product revenue yet. Their upside is tied to trial data in large unmet-need cancer settings, but each still carries high clinical and cash-burn risk.
| Asset | Q-Mark reason | Key risk |
|---|---|---|
| ERAS-007 | Early oral ERK1/2 inhibitor | Data not yet proven |
| ERAS-601 | Early oral SHP2 inhibitor | Differentiation unclear |
| ERAS-801 | Early CNS EGFR inhibitor | Clinical success uncertain |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.